Pamela J. Cramer - Aug 26, 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Human Resources Officer
Signature
/s/ Hunter Smith, attorney-in-fact for Pamela J. Cramer
Stock symbol
RYTM
Transactions as of
Aug 26, 2024
Transactions value $
-$99,154
Form type
4
Date filed
8/28/2024, 04:31 PM
Previous filing
Aug 13, 2024
Next filing
Sep 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $60.9K +3.2K +23.7% $19.02 16.7K Aug 26, 2024 Direct
transaction RYTM Common Stock Sale -$160K -3.2K -19.16% $50.01 13.5K Aug 26, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Options (Right to buy) Options Exercise $0 -3.2K -10.41% $0.00 27.5K Aug 26, 2024 Common Stock 3.2K $19.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024.
F2 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3 The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.